economictimes.indiatimes.com ·
Share Final Dividend
Topic context
This topic has been covered 377457 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedGland Pharma's strong earnings and dividend announcement reflect robust CDMO demand and operational efficiency. The impact is company-specific, with no direct commodity or supply-chain scarcity. The stock surged 11% on the news, but the commercial mechanism is limited to the company's own revenue and margin expansion.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Gland Pharma Q4 FY26 net profit up 97% YoY to Rs 366.7 crore
- Revenue up 22% YoY to Rs 1,742.8 crore
- CDMO segment contributed 46% of total revenues
- FY26 adjusted EBITDA margin at 26%
- Final dividend of Rs 20 per share proposed
CDMO services and generic injectables are expected to remain flat in the mid-term, with a slight positive movement of 1-2% over 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Canaan Can Q1 2026 Earnings Transcript
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com